Pharmtechnology, LLC
- Country
- 🇧🇾Belarus
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://ft.by/en/okomp-2
A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 28
- Registration Number
- NCT03898011
- Locations
- 🇷🇺
State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2", Yaroslavl, Yaroslavl Region, Russian Federation
Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 36
- Registration Number
- NCT03799536
- Locations
- 🇧🇾
National Anti-Doping Laboratory, Settl.Lesnoy, Minsk Region, Belarus
Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 26
- Registration Number
- NCT03705533
- Locations
- 🇨🇦
Algorithme Pharma, An Altasciences Company, Mount-Royal, Quebec, Canada
Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 56
- Registration Number
- NCT03702894
- Locations
- 🇷🇺
State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2", Yaroslavl, Yaroslavl Region, Russian Federation
Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 56
- Registration Number
- NCT03616301
- Locations
- 🇷🇺
State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2", Yaroslavl, Yaroslavl Region, Russian Federation
Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting Conditions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03561558
- Locations
- 🇷🇺
State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2", Yaroslavl, Yaroslavl Region, Russian Federation
A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 66
- Registration Number
- NCT03459911
- Locations
- 🇮🇳
Clinical Unit, Reliance Life Sciences Pvt. Ltd., Mumbai, Maharashtra, India